GlassScriptPhysician profile
Cheryl K Verma
NPI 1588807655
$2,495.46
in general payments reported to CMS, 2019-2025
28 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $346 · 2023: $531 · 2024: $907 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.55 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $328.75 | 2022-2025 | |
| Amgen INC. | $307.55 | 2021-2025 | Repatha, Evenity, Prolia |
| Pfizer INC. | $181.90 | 2022-2025 | |
| Abbott Laboratories | $121.97 | 2022-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $91.45 | 2022-2025 | Eliquis |
| Lilly USA, LLC | $90.56 | 2024 | Zepbound, Jardiance |
| Dexcom, INC. | $88.54 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.69 | 2024-2025 | Jardiance, Synjardy, Ofev |
| Corcept Therapeutics | $70.61 | 2025 | Korlym |
| Eisai INC. | $65.75 | 2021-2025 | |
| Evoke Pharma, INC. | $59.45 | 2022-2025 | |
| Novo Nordisk INC | $56.68 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $54.09 | 2023-2024 | Shingrix |
| Alnylam Pharmaceuticals INC. | $40.61 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $40.32 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $35.35 | 2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $28.44 | 2022 | |
| Boston Scientific Corporation | $21.03 | 2024 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.89 | 2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $16.78 | 2022 | |
| Amarin Pharma, INC. | $14.92 | 2021 | |
| Merck Sharp & Dohme LLC | $14.61 | 2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $13.80 | 2024 | Veozah |
| Esperion Therapeutics, INC. | $13.11 | 2021 | |
| Nevro Corp. | $13.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.95 | 2023 | Xarelto |
| Braintree Laboratories, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.